FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213046593> ?p ?o ?g. }

• W4213046593 abstract "Abstract Background Many second-generation antipsychotics (SGAs) are associated with weight gain and cardiometabolic effects. Antipsychotic-associated weight gain is linked to treatment interruptions, potentially increasing risk of relapse and hospitalization. This retrospective study assessed clinically significant weight gain (CSWG), treatment interruptions, and development of cardiometabolic conditions in patients with schizophrenia (SZ) or bipolar I disorder (BD-I) following initiation of oral SGAs with moderate to high weight gain risk. Methods Patients with no prior use of moderate to high weight gain risk oral SGAs were identified from patient-level medical/pharmacy claims and electronic medical records (January 2013–February 2020; OM1 Real-World Data Cloud). Those with ≥ 1 weight measurement in both the 12 months preceding and 3 months after SGA initiation (index date) were analyzed for continuous changes in weight, CSWG (≥ 7% and ≥ 10% increases from baseline), treatment interruptions (switches/discontinuations), and development of cardiometabolic conditions. Results Median follow-up times in the SZ ( n = 8174) and BD-I ( n = 9142) cohorts were 153.4 and 159.4 weeks, respectively; 45.5% and 50.7% were obese at baseline. Mean (SD) percent weight increase during treatment was 3.3% (7.2) and 3.7% (7.0) for patients with SZ and BD-I, respectively, and was highest for underweight/normal weight patients (SZ: 4.8% [8.1]; BD-I: 5.5% [8.7]). More than 96% had treatment interruptions during follow-up, primarily discontinuations. CSWG and treatment interruptions occurred within a median of 13 and 14 weeks after treatment initiation, respectively. Of patients with CSWG and treatment interruptions, approximately 75% did not return to baseline weight during follow-up. Among those without baseline cardiometabolic conditions, 14.7% and 11.3% of patients with SZ or BD-I, respectively, developed ≥ 1 condition over 12 months post-index. Incidence was generally highest among those who were overweight/obese at baseline and those who experienced CSWG. Conclusions In this analysis of real-world data, both weight gain and treatment interruptions occurred early in treatment for patients with SZ or BD-I. Treatment-associated weight gain persisted despite switching or discontinuing index treatment. Additionally, cardiometabolic morbidity increased within 12 months of treatment initiation. Patients with SZ or BD-I are at greater risk than the general population for cardiometabolic conditions; weight gain associated with SGAs may exacerbate these health risks." @default.
• W4213046593 created "2022-02-24" @default.
• W4213046593 creator A5003373914 @default.
• W4213046593 creator A5009905661 @default.
• W4213046593 creator A5014578436 @default.
• W4213046593 creator A5022474346 @default.
• W4213046593 creator A5040975535 @default.
• W4213046593 creator A5047246416 @default.
• W4213046593 creator A5058232216 @default.
• W4213046593 creator A5063886881 @default.
• W4213046593 creator A5091319547 @default.
• W4213046593 creator A5091424151 @default.
• W4213046593 date "2022-02-14" @default.
• W4213046593 modified "2023-10-01" @default.
• W4213046593 title "Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder" @default.
• W4213046593 cites W1532689205 @default.
• W4213046593 cites W1571256252 @default.
• W4213046593 cites W1966020199 @default.
• W4213046593 cites W1971684447 @default.
• W4213046593 cites W1993446055 @default.
• W4213046593 cites W1997542765 @default.
• W4213046593 cites W1999134535 @default.
• W4213046593 cites W2000936213 @default.
• W4213046593 cites W2007447972 @default.
• W4213046593 cites W2042196761 @default.
• W4213046593 cites W2045232247 @default.
• W4213046593 cites W2054444042 @default.
• W4213046593 cites W2055105374 @default.
• W4213046593 cites W2059717138 @default.
• W4213046593 cites W2081329741 @default.
• W4213046593 cites W2084556419 @default.
• W4213046593 cites W2089001223 @default.
• W4213046593 cites W2105527159 @default.
• W4213046593 cites W2116251861 @default.
• W4213046593 cites W2128852739 @default.
• W4213046593 cites W2138418531 @default.
• W4213046593 cites W2146830005 @default.
• W4213046593 cites W2153393568 @default.
• W4213046593 cites W2154493342 @default.
• W4213046593 cites W2159155203 @default.
• W4213046593 cites W2170987846 @default.
• W4213046593 cites W2418402824 @default.
• W4213046593 cites W2480974182 @default.
• W4213046593 cites W2728473268 @default.
• W4213046593 cites W2746379998 @default.
• W4213046593 cites W2756227090 @default.
• W4213046593 cites W2792027821 @default.
• W4213046593 cites W2793368865 @default.
• W4213046593 cites W3018680094 @default.
• W4213046593 cites W3038770835 @default.
• W4213046593 cites W3097393482 @default.
• W4213046593 cites W47623468 @default.
• W4213046593 doi "https://doi.org/10.1186/s12888-022-03758-w" @default.
• W4213046593 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35164737" @default.
• W4213046593 hasPublicationYear "2022" @default.
• W4213046593 type Work @default.
• W4213046593 citedByCount "5" @default.
• W4213046593 countsByYear W42130465932022 @default.
• W4213046593 countsByYear W42130465932023 @default.
• W4213046593 crossrefType "journal-article" @default.
• W4213046593 hasAuthorship W4213046593A5003373914 @default.
• W4213046593 hasAuthorship W4213046593A5009905661 @default.
• W4213046593 hasAuthorship W4213046593A5014578436 @default.
• W4213046593 hasAuthorship W4213046593A5022474346 @default.
• W4213046593 hasAuthorship W4213046593A5040975535 @default.
• W4213046593 hasAuthorship W4213046593A5047246416 @default.
• W4213046593 hasAuthorship W4213046593A5058232216 @default.
• W4213046593 hasAuthorship W4213046593A5063886881 @default.
• W4213046593 hasAuthorship W4213046593A5091319547 @default.
• W4213046593 hasAuthorship W4213046593A5091424151 @default.
• W4213046593 hasBestOaLocation W42130465931 @default.
• W4213046593 hasConcept C118552586 @default.
• W4213046593 hasConcept C126322002 @default.
• W4213046593 hasConcept C147583825 @default.
• W4213046593 hasConcept C187212893 @default.
• W4213046593 hasConcept C2776174506 @default.
• W4213046593 hasConcept C2776412080 @default.
• W4213046593 hasConcept C2780221984 @default.
• W4213046593 hasConcept C2780320433 @default.
• W4213046593 hasConcept C2780494398 @default.
• W4213046593 hasConcept C2780586474 @default.
• W4213046593 hasConcept C2780733359 @default.
• W4213046593 hasConcept C2781121325 @default.
• W4213046593 hasConcept C3017894415 @default.
• W4213046593 hasConcept C511355011 @default.
• W4213046593 hasConcept C544821477 @default.
• W4213046593 hasConcept C71924100 @default.
• W4213046593 hasConceptScore W4213046593C118552586 @default.
• W4213046593 hasConceptScore W4213046593C126322002 @default.
• W4213046593 hasConceptScore W4213046593C147583825 @default.
• W4213046593 hasConceptScore W4213046593C187212893 @default.
• W4213046593 hasConceptScore W4213046593C2776174506 @default.
• W4213046593 hasConceptScore W4213046593C2776412080 @default.
• W4213046593 hasConceptScore W4213046593C2780221984 @default.
• W4213046593 hasConceptScore W4213046593C2780320433 @default.
• W4213046593 hasConceptScore W4213046593C2780494398 @default.
• W4213046593 hasConceptScore W4213046593C2780586474 @default.
• W4213046593 hasConceptScore W4213046593C2780733359 @default.
• W4213046593 hasConceptScore W4213046593C2781121325 @default.
• W4213046593 hasConceptScore W4213046593C3017894415 @default.

• next